ABL Bio said on the 11th that at the World Bispecific & T-Cell Engager Summit South Korea, it introduced the efficacy and safety of its bispecific antibody platform "Grabody-T," which is based on the T-cell (immune cell) costimulatory receptor (4-1BB).
The event was organized to share the latest research trends and technological innovations in the development of bispecific antibodies and T-cell engagers, which are drawing attention as next-generation cancer treatment strategies. In particular, Korea is regarded as a global key market where research and development on bispecific antibodies is active among many biotech companies, and global pharmaceutical companies and industry experts attended to discuss cooperation plans.
On the second day of the event, on the 10th, ABL Bio gave a presentation on the theme of "optimizing T-cell engagers from preclinical research to clinical trials." At the session, the company introduced the working mechanism of the Grabody-T platform and its clinical development results.
Grabody-T is a bispecific antibody development platform that simultaneously targets 4-1BB, which is involved in T-cell activation, and tumor-associated antigens (TAA). The company said that while 4-1BB can raise concerns about serious hepatotoxicity if developed as a monotherapy target, designing it in a bispecific antibody format can activate T-cells only in the tumor microenvironment where cancer cells are present, improving safety.
Key pipelines applying Grabody-T include "gevastomig (ABL111)" and "razistomig (ABL503)." The two candidates confirmed anticancer efficacy and safety in clinical trials. Gevastomig is currently in phase 2 as a first-line treatment for gastric cancer in combination with chemotherapy and a PD-1 inhibitor. Razistomig recently expanded the scope of development to include combination therapy with a PD-1 inhibitor from a phase 1 study focused on monotherapy.
Chief Executive Lee Sang-hoon of ABL Bio said, "Bispecific antibodies are establishing themselves as next-generation technology to address unmet needs in the treatment of solid tumors," and added, "4-1BB, too, is drawing growing interest from the global industry as it demonstrates excellent safety and efficacy in the clinic through a bispecific structure."
Lee continued, "This presentation was meaningful as we were able to share the differentiated competitiveness and clinical development results of the Grabody-T platform," and said, "We will accelerate clinical development of key pipelines and expand global partnerships to grow into a leading company in the bispecific antibody field."